Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Vivoryon Therapeutics

Vivoryon Therapeutics
1997 FOUNDED
PUBLIC STATUS
11-20 EMPLOYEES
VVY STOCK SYMBOL
1 INVESTMENTS
$7.40 SHARE PRICE (As of Tuesday Closing)
Description

Vivoryon Therapeutics AG is a Germany based biopharmaceutical company engaged in the activities of research and development, preclinical and clinical trials. It is focused on the development of therapeutic products for the treatment of Alzheimer's disease and cancer. The company's pipeline products includes PQ912, PQ1565 and PQ-family.

Formerly Known As
ProBioTec, Probiodrug
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Stock Exchange
AMS
Primary Office
  • Weinbergweg 22
  • 06120 Halle
  • Germany

+49 0345 0000000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Vivoryon Therapeutics’s full profile, request a free trial.

Vivoryon Therapeutics Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
$1.27 - $9.46 $148M $7.48 -$0.83 83.1K 20M

Vivoryon Therapeutics Financials Summary

In Thousands,
USD
TTM
30-Jun-2019
FY 2018
31-Dec-2018
FY 2017
31-Dec-2017
FY 2016
31-Dec-2016
Enterprise Value 72,739 16,423 87,327 126,957
Revenue 0 0 0 0
EBITDA (8,237) (9,057) (11,114) (15,132)
Net Income (8,331) (9,130) (9,032) (15,365)
Total Assets 10,342 4,631 12,911 23,522
Total Debt 0 0 0 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Vivoryon Therapeutics Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Vivoryon Therapeutics‘s full profile, request access.

Request full access to PitchBook

Vivoryon Therapeutics Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000000 000000000 25-Jun-2007 000000000000000000 Pharmaceuticals
To view this company’s complete investment and acquisition history, request access »

Vivoryon Therapeutics Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Vivoryon Therapeutics‘s full profile, request access.

Request full access to PitchBook

Vivoryon Therapeutics Executive Team (12)

Name Title Board
Seat
Contact
Info
Ulrich Dauer Chief Executive Officer
Kerstin Kühn-Wache Director, Project Management
Hans-Ulrich Demuth Scientific Advisor and Co-Founder
Ulrich Heiser Senior Director, Medicinal Chemistry
Michael Schaeffer Ph.D Chief Business Officer

7 Former Executives

You’re viewing 5 of 12 executives. Get the full list »